

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTACDR1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	4	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	5	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	6	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	7	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	8	FEB 10	COMPENDEX reloaded and enhanced
NEWS	9	FEB 11	WTEXTILES reloaded and enhanced
NEWS	10	FEB 19	New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art
NEWS	11	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	12	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	13	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	14	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	15	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	16	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	17	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	18	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	19	MAR 11	ESBIOBASE reloaded and enhanced
NEWS	20	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS	21	MAR 23	CA/CAPLUS enhanced with more than 250,000 patent equivalents from China
NEWS	22	MAR 30	IMSPATENTS reloaded and enhanced
NEWS	23	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS EXPRESS	JUNE 27 08	CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.	
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:31:27 ON 06 APR 2009

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 12:31:36 ON 06 APR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 APR 2009 HIGHEST RN 1132636-28-2

DICTIONARY FILE UPDATES: 5 APR 2009 HIGHEST RN 1132636-28-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10564139s1.str



```

chain nodes :
13
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 14 15 16 17 18 19 20 21 22
chain bonds :
6-7 10-13 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 14-15 14-19
15-16 16-17 16-20 17-18 17-22 18-19 20-21 21-22
exact/norm bonds :
6-7 7-8 7-12 8-9 9-10 10-11 10-13 11-12 16-20 17-22 20-21 21-22
exact bonds :
13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 12:31:58 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 56 TO ITERATE

100.0% PROCESSED 56 ITERATIONS

12 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH      \*\*COMPLETE\*\*  
PROJECTED ITERATIONS:      671 TO      1569  
PROJECTED ANSWERS:      33 TO      447

L2      12 SEA SSS SAM L1

=> s l1 sss full  
FULL SEARCH INITIATED 12:32:02 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED -      1306 TO ITERATE

100.0% PROCESSED      1306 ITERATIONS      301 ANSWERS  
SEARCH TIME: 00.00.01

L3      301 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS      SINCE FILE      TOTAL  
ENTRY      SESSION  
FULL ESTIMATED COST      185.88      186.10

FILE 'CAPLUS' ENTERED AT 12:32:06 ON 06 APR 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Apr 2009 VOL 150 ISS 15  
FILE LAST UPDATED: 5 Apr 2009 (20090405/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3  
L4      482 L3  
  
=> s l3 and cyclodextrin  
482 L3  
39726 CYCLODEXTRIN  
11071 CYCLODEXTRINS  
40770 CYCLODEXTRIN  
          (CYCLODEXTRIN OR CYCLODEXTRINS)  
L5      6 L3 AND CYCLODEXTRIN  
  
=> d ibib abs hitstr 1-6

L5 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1359892 CAPLUS

DOCUMENT NUMBER: 149:519140

TITLE: Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders

INVENTOR(S): Braun, Marina; Schollmayer, Erwin; Sachse, Richard

PATENT ASSIGNEE(S): Schwarz Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 58pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008135527	A2	20081113	WO 2008-EP55413	20080502
WO 2008135527	A3	20090212		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1987815	A1	20081105	EP 2007-9013	20070504
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			

PRIORITY APPLN. INFO.:

EP 2007-9013 A 20070504

US 2007-915964P P 20070504

AB The present invention relates to use of a dopamine agonist such as rotigotine for the preparation of an oronasopharyngeally deliverable pharmaceutical composition for the prevention/alleviation and/or treatment of restless limb disorder, as well as pharmaceutical articles, dosage units and pharmaceutical kits useful in practicing the invention. Thus, intranasal formulation was prepared containing rotigotine hydrochloride 2.5

g/l,


$\alpha$ - cyclodextrin 85 g/l, sodium chloride 8 g/l, potassium chloride 0.2 g/l, disodium hydrogen phosphate dihydrate 1.44 g/l, potassium dihydrogen phosphate 0.2 g/l, glycerol 31.2 g/l, water to add up to final volume, and citric acid for pH adjustment (pH of solution 5.8).

IT 3605-01-4, Piribedil

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(oronasopharyngeally deliverable pharmaceutical compns. of dopamine agonists for prevention and/or treatment of restless limb disorders)

RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



L5 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2008:1324859 CAPLUS  
 DOCUMENT NUMBER: 149:500102  
 TITLE: Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders  
 PATENT ASSIGNEE(S): Schwarz Pharma A.-G., Germany  
 SOURCE: Eur. Pat. Appl., 33pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1987815	A1	20081105	EP 2007-9013	20070504
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
US 20080274061	A1	20081106	US 2008-114348	20080502
WO 2008135527	A2	20081113	WO 2008-EP55413	20080502
WO 2008135527	A3	20090212		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.: EP 2007-9013 A 20070504  
 US 2007-915964P P 20070504

AB The present invention relates to use of a dopamine agonist such as rotigotine for the preparation of an oronasopharyngeally deliverable pharmaceutical composition for the prevention/alleviation and/or treatment of restless limb disorder, as well as pharmaceutical articles, dosage units and pharmaceutical kits useful in practicing the invention. Thus, intranasal formulation was prepared containing rotigotine hydrochloride 2.5

g/l,


$\alpha$ - cyclodextrin 85 g/l, sodium chloride 8 g/l, potassium chloride 0.2 g/l, disodium hydrogen phosphate dihydrate 1.44 g/l, potassium dihydrogen phosphate 0.2 g/l, glycerol 31.2 g/l, water to add up to final volume, and citric acid for pH adjustment (pH of solution 5.8).

IT 3605-01-4, Piribedil

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (oronasopharyngeally deliverable pharmaceutical compns. of dopamine agonists for prevention and/or treatment of restless limb disorders)

RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:645606 CAPLUS

DOCUMENT NUMBER: 145:460196

TITLE: Enhancement in dissolution pattern of piribedil by molecular encapsulation with  $\beta$ -cyclodextrin

AUTHOR(S): Demirel, M.; Buyukkoroglu, G.; Kalava, B. S.; Yazan, Y.

CORPORATE SOURCE: Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskisehir, Turk.

SOURCE: Methods and Findings in Experimental and Clinical Pharmacology (2006), 28(2), 83-88  
CODEN: MFEPDX; ISSN: 0379-0355

PUBLISHER: Prous Science

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The aim of this study was to improve the dissoln. behavior of piribedil by mol. encapsulation with  $\beta$ - cyclodextrin ( $\beta$ -CD). Toward this aim, phys. mixing, co-grinding, and spray-drying methods were used to prepare solid binary systems. Differential scanning calorimetry, X-ray diffractometry, and particle size anal. were used to characterize the binary systems obtained. Complexes of piribedil and  $\beta$ -CD could be prepared using the spray-drying method. Dissoln. of piribedil was improved to a great extent by the complex prepared


IT 3605-01-4, Piribedil

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(mol. encapsulation of piribedil with  $\beta$ - cyclodextrin using spray-drying method showed enhanced dissoln. pattern)

RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:56829 CAPLUS

DOCUMENT NUMBER: 142:141273

TITLE: Pharmaceutical composition for the nasal  
 administration of piribedil  
 INVENTOR(S): Rolland, Herve; Wuthrich, Patrick  
 PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.; Servier Lab  
 SOURCE: Fr. Demande, 9 pp.  
 CODEN: FRXXBL  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2857594	A1	20050121	FR 2003-8712	20030717
FR 2857594	B1	20050916		
AU 2004258714	A1	20050203	AU 2004-258714	20040716
CA 2532631	A1	20050203	CA 2004-2532631	20040716
WO 2005009442	A1	20050203	WO 2004-FR1867	20040716
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1653963	A1	20060510	EP 2004-767691	20040716
EP 1653963	B1	20061227		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1819828	A	20060816	CN 2004-80019749	20040716
BR 2004012681	A	20061003	BR 2004-12681	20040716
AT 349213	T	20070115	AT 2004-767691	20040716
JP 2007516947	T	20070628	JP 2006-519966	20040716
ES 2279435	T3	20070816	ES 2004-767691	20040716
NZ 544460	A	20080430	NZ 2004-544460	20040716
IN 2006DN00118	A	20070824	IN 2006-DN118	20060106
US 20060204449	A1	20060914	US 2006-564139	20060110
MX 2006000641	A	20060330	MX 2006-641	20060117
KR 2006031689	A	20060412	KR 2006-701141	20060117
KR 807480	B1	20080225		
NO 2006000743	A	20060216	NO 2006-743	20060216
PRIORITY APPLN. INFO.:			FR 2003-8712	A 20030717
			WO 2004-FR1867	W 20040716
AB	The present invention relates to a pharmaceutical composition for the nasal administration of piribedil in solution or powder forms. Thus, a formulation contained piribedil 100, Rameb (randomly methylated cyclodextrin ) 750, and NaCl 68 mg, and water qs to 10 mL.			
IT	3605-01-4, Piribedil RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical composition for nasal administration of piribedil)			
RN	3605-01-4 CAPLUS			
CN	Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)			



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:988974 CAPLUS

DOCUMENT NUMBER: 124:66420

ORIGINAL REFERENCE NO.: 124:12273a,12276a

TITLE: Effects of  $\beta$ - cyclodextrins on skin: implications for the transdermal delivery of piribedil and a novel cognition enhancing-drug, S-9977

AUTHOR(S): Legendre, J. Y.; Rault, I.; Petit, A.; Luijten, W.; Demuynck, I.; Horvath, S.; Ginot, Y. M.; Cuine, A.

CORPORATE SOURCE: Ardix, Rue Eugene Vignat, Orleans, 45000, Fr.

SOURCE: European Journal of Pharmaceutical Sciences (1995), 3(6), 311-22

CODEN: EPSCED; ISSN: 0928-0987

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The effects of  $\beta$ - cyclodextrin ( $\beta$ -CD), randomly methylated  $\beta$ - cyclodextrin (RAMEB) and 2-hydroxypropyl  $\beta$ - cyclodextrin (HP $\beta$ -CD) on skin were investigated. The three cyclodextrins (CDs) were able to destabilize model liposomes and to extract significant amts. of cholesterol from isolated stratum corneum (SC). However, only RAMEB extracted all the major lipid classes from isolated SC, as shown by thin layer chromatog. Both RAMEB and HP $\beta$ -CD could release 5-10% of the extractable cholesterol as well as proteins from hairless rat skin. Nevertheless, CDs did not induce any major modification of the differential scanning calorimetry (DSC) profile or the Fourier-transformed IR (FTIR) spectrum of SC. This was explained by the low percutaneous penetration of CDs. Furthermore, the influence of RAMEB on the transdermal diffusion through hairless rat skin of piribedil, a central dopaminergic agonist and of S-9977, a novel cognition enhancing drug, was studied. RAMEB was found to decrease the transdermal flux of piribedil, with which it forms an inclusion complex, as shown by NMR. Conversely, RAMEB increased by 2-fold the percutaneous absorption of the S-9977 hydrochloride, which does not interact with CD. Finally, a combination of oleic acid and RAMEB greatly increased by about 30-fold the flux of S-9977 hydrochloride.

IT 3605-01-4, Piribedil

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (effects of  $\beta$ - cyclodextrins on skin: implications for the transdermal delivery of piribedil and a novel cognition enhancing-drug, S-9977)

RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



L5 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:726272 CAPLUS

DOCUMENT NUMBER: 123:123180

ORIGINAL REFERENCE NO.: 123:21721a, 21724a

TITLE: Pharmaceutical compositions containing partially methylated  $\beta$ -cyclodextrines as absorption promoters

INVENTOR(S): Cuine, Alain; De Jong, Hendrik J.

PATENT ASSIGNEE(S): Adir et Cie., Fr.

SOURCE: Can. Pat. Appl., 9 pp.

CODEN: CPXXEB

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2132511	A1	19950323	CA 1994-2132511	19940920
FR 2710268	A1	19950331	FR 1993-11258	19930922
FR 2710268	B1	19951020		
EP 649653	A1	19950426	EP 1994-402061	19940915
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AU 9474111	A	19950406	AU 1994-74111	19940920
JP 07247223	A	19950926	JP 1994-226875	19940921
ZA 9407401	A	19950515	ZA 1994-7401	19940922

PRIORITY APPLN. INFO.: FR 1993-11258 A 19930922


AB Partially methylated  $\beta$ -cyclodextrines are used as absorption promoters in transdermal pharmaceutical compns. A pharmaceutical lotion contained estradiol (I) 5, dimethyl- $\beta$ - cyclodextrin (II) 48.875 g, NaOH solution q.s. pH = 7.4, and water q.s. 1000mL. The flux of I in hairless rat skin was 2.4 as compared with 1.2  $\mu\text{g}/\text{cm}^2/\text{h}$  for controls having no II.

IT 3605-01-4, Piribedil

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical compns. containing partially methylated  $\beta$ -cyclodextrines as absorption promoters)

RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y  
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
41.08	227.18

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE	TOTAL
ENTRY	SESSION
-4.92	-4.92

STN INTERNATIONAL LOGOFF AT 12:37:55 ON 06 APR 2009